GSK will be fine. What they need to do is what Novartis did a few years ago....get rid of ~50% of the reps and mgrs. Way too many calling on NO see offices. The vaccine div will continue to do well. The OTC is very good business, much like Parke-Davis had 3 different group of business. The resp. div. a mess....they need a breath of fresh air...get it!!
What the hell are you talking about? Respiratory is all we have! Generates 80% of the pharmaceutical divisions sales. Not Nucala. Not benlysta. Certainly not vaccines. Yes, you could easily get rid of half the managers..easily. Maybe 25% of the reps.
Resp. sales will fall to about 1/2 of what they are now. Breo, Incruse a good drugs. But the profits are in vaccines and otc. Shingrix will be a big seller...and look for GSK to let a few of you blokes go!!
Another millennial wanting to be Nostradamus. So darned smart he makes me cry. Wish he had control of the company to lead us in the right direction.